ClinicalTrials.gg
Not yet recruitingNCT07440381PERSUADEUpdated Feb 27, 2026

triPle Oral thERapy With Bempedoic Acid vs uSual Care in Early Lipid Management of Patients With acUte coronAry synDromE

A Phase 3 interventional study of Triple oral lipid lowering treatment in Acute Coronary Syndromes, Secondary Prevention and Lipids, sponsored by Heart Care Foundation. Not yet recruiting at 35 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Heart Care Foundation · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 138 studies in Acute Coronary Syndrome with a site in Italy — 25 open to participants now, 29 under way, 2 of them phase 3. Acute Coronary Syndrome · Italy.

Planned enrollment
41st of 85
600 · median 522
Started
2026
with 4 others
Phase 3
27 of 138
2 open now
Primary completion
2027-08
later than 18 of 28 live
Registered
133rd of 138
by date
Lead sponsor
6 of 138
Heart Care Foundation

Among the 138 studies in Acute Coronary Syndrome with a site in Italy, this one is the 41st largest by planned enrollment of the 85 interventional ones that give a count, is one of 5 that started in 2026, is one of 27 in phase 3, reaches primary completion later than 18 of the 28 other live ones, and was the 133rd registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

25 of the 138 studies in Acute Coronary Syndrome with a site in Italy are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 195 Acute Coronary Syndrome studies recruiting now, 144 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 138 studies in Acute Coronary Syndrome with a site in Italy, or all of them as a file.
02

Study summary

Early and intensive LDL-cholesterol (LDL-c) reduction is associated with improved short-term and long-term outcomes. Bempedoic acid is an oral ATP citrate lyase inhibitor that lowers LDL-c upstream of HMG-CoA reductase. When added to maximally tolerated statins, it has demonstrated significant LDL-c reduction and cardiovascular benefit, particularly in statin-intolerant or high-risk patients. However, evidence on early initiation of bempedoic acid during the index ACS hospitalization is currently lacking. The investigators therefore would like to see whether early (pre-discharge) initiation of an oral triple lipid-lowering therapy including bempedoic acid, high-intensity statin (HIS), and ezetimibe is superior to usual care in reducing LDL-c levels at 8 weeks after randomization in patients hospitalized for ACS.

Read the detailed description

Despite major improvements in the acute management of Acute Coronary Syndromes (ACS), recurrent cardiovascular events remain frequent after hospital discharge. Real-world registries consistently show suboptimal implementation of guideline-recommended lipid-lowering strategies, with more than 60% of patients failing to achieve recommended LDL-cholesterol (LDL-c) targets after ACS. Early and intensive LDL-c reduction is associated with improved short-term and long-term outcomes. While injectable lipid-lowering therapies such as PCSK9 inhibitors have demonstrated rapid LDL-c reduction when initiated early after ACS, their high cost and parenteral administration limit widespread adoption. Bempedoic acid is an oral ATP citrate lyase inhibitor that lowers LDL-c upstream of HMG-CoA reductase. When added to maximally tolerated statins, it has demonstrated significant LDL-c reduction and cardiovascular benefit, particularly in statin-intolerant or high-risk patients. However, evidence on early initiation of bempedoic acid during the index ACS hospitalization is currently lacking.

03

Conditions studied

  • Acute Coronary Syndromes
  • Secondary Prevention
  • Lipids

Keywords

  • ACS
  • Lipid-lowering therapy
  • atherothrombotic coronary event
  • secondary prevention
  • triple oral lipid lowering therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • Male and females at birth
  • Admitted for ACS caused by an atherothrombotic coronary event;
  • Calculated LDL-c: 70-140 mg/dL within 24 hours from admission for the ACS index event
  • Lipid lowering therapy on admission consisting of a low/moderate intensity statin or a high intensity statin (HIS); or no lipid lowering therapy (naïve patients)
  • Lipid-lowering therapy at discharge (at the time of randomization) consisting of HIS or HIS + ezetimibe
  • Scheduled home discharge
  • Written provided; patients who are unable to give informed consent for any reason will be excluded from the study.

Exclusion criteria

Exclusion Criteria:

  • Patients already treated with HIS+Ezetimibe on admission for the ACS event,
  • Patients currently, previously or planned to be treated with PCSK9i or inclisiran,
  • Patients treated currently or in the last 3 months with bempedoic acid or in whom this treatment is planned in the following 8 weeks,
  • Known allergy, sensitivity or intolerance to bempedoic acid and/or study drugs' formulation ingredients (e.g. lactose intolerance),
  • Patients with history of documented intolerance to statins, ezetimibe or bempedoic acid
  • Patients with known Familial Hypercholesterolemia (FH; heterozygous or homozygous),
  • Patients with plasma triglycerides concentration exceeding 400 mg/dL (4.52 mmol/L),
  • Patients with dysbetalipoproteinemia (type III hyperlipoproteinemia),
  • Unstable clinical status (hemodynamic or electrical instability),
  • Severe renal dysfunction ( \<30 ml/min/1.73m2 using the CKD-EPI formula),
  • Active liver disease or hepatic dysfunction ( or ALT levels > 3xUNL),
  • Current enrolment in another device or drug study,
  • Current pregnancy, lactation or women of , unless using highly effective ,
  • Patients unlikely to comply with the protocol or unable to understand the nature, scope and possible consequences of the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
600 participants (estimated)

Study arms

  • No intervention
    Control

    Usual Care

  • Experimental
    High intensity statin plus ezetimibe plus bempedoic acid

    patients will receive a triple oral lipid lowering therapy including a high intensity statin, ezetimibe and bempedoic acid

    Drug: Triple oral lipid lowering treatment

Interventions

  • DrugTriple oral lipid lowering treatment

    Triple oral lipid lowering treatment including high intensity statin, ezetimibe and bembedoic acid

06

What researchers measure

Primary outcomes

  1. Mean percent change in LDL-c levels

    the difference in the mean percent change in LDL-c levels from baseline at 8 weeks between triple combo therapy and usual care.

    Time frame: 8 weeks

Secondary outcomes

  1. Percentage of patients with LDL-c level <70 mg/dL

    Difference in percentage of patients with LDL-c level \<70 mg/dL at 8 weeks

    Time frame: 8 weeks

  2. Percentage of patients with LDL-c level <55 mg/dL

    Difference in percentage of patients with LDL-c level \<55 mg/dL at 8 weeks

    Time frame: 8 weeks

  3. Percentage of patients with LDL-c level <40 mg/dL in those with a recurrent ACS event in the previous 48 months

    Difference in percentage of patients with LDL-c level \<40 mg/dL at 8 weeks in those with a recurrent ACS event in the previous 48 months

    Time frame: 8 weeks

  4. Change in high-sensitivity CRP (hs-CRP)

    Change in high-sensitivity CRP (hs-CRP) at 8 weeks

    Time frame: 8 weeks

  5. Persistence of active treatment and discontinuation rate

    Rate of persistence of active treatment and discontinuation rate of allocated treatment

    Time frame: 8 weeks

  6. Rate of adverse events

    Safety of the investigational study drug by adverse event recording

    Time frame: 8 weeks

  7. Rate of adverse events

    Safety of the investigational study drug by adverse event recording

    Time frame: 3 months

07

Study locations

35 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Aug 2027, 11 months later.

Of 39 phase 3 interventional studies under Acute Coronary Syndrome, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 52. This study's planned 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2026
First posted
Feb 27, 2026
StartEst.
Sep 2026
Primary completionEst.
Aug 2027
CompletionEst.
Aug 2027
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07440381
Lead sponsor
Heart Care Foundation
Responsible party
Sponsor
First posted
Feb 27, 2026
Start date
Sep 2026 (estimated)
Primary completion
Aug 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Feb 27, 2026

Study contacts

Francesco Orso, MD
Contact
persuade@heartcarefoundation.it
+390555101230
Furio Colivicchi, MD
study chair · San Filippo neri Hospital - Rome
Aldo P Maggioni, MD
study chair · Fondazione per il Tuo cuore
Pietro Scicchitano, MD
study chair · Ospedale Miulli - Bari

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion